Anticardiolipin antibodies and cardiovascular disease
The provocative article by Dr Muir (August 1995 jRSM, pp433-436) cannot go unchallenged. It ignores the existence of large international consensus groups working closely on both laboratory standardization of antiphospholipid antibodies and their isotypes and collaborative prospective treatment trials.
Muir questions the influence of a positive anticardiolipin antibodies (aCL) assay on patient management and states 'there is no therapeutic difference between patients with or without elevated aCL titre'. Although their relevance in acute stroke, venous thrombosis and cardiac disease in the general population is still debated, in the field of obstetric medicine, the presence or absence of aCL may be the single most important factor determining management strategies for the pregnant patient.
Antiphospholipid antibodies are the most frequent cause of acquired thrombophilia.
Detection therefore constitutes an indication for antenatal thromboprophylaxis with heparin in women with a history of thromboembolism 1. Furthermore, the risk of recurrent thrombosis in patients with antiphospholipid syndrome (APS) is so high (70%) that long-term anticoagulation may be needed in these patients-.
We take issue with the author's statement that 'there is no good evidence of a titrerelated risk for aCL'. Several workers have described the correlation between the titre of aCL and the risk to the fetus 3-5. Women with APS are particularly prone to second trimester loss, and controlled clinical trials support treatment with low-dose aspirin (75 mg/day) and subcutaneous heparin in preference to eorticosteroids in those with previous fetal loss6. Even in pregnancies which do not end in miscarriage, there is an increased risk of severe pre-eclampsia7, and antenatal surveillance is increased in such women.
The most persuasive evidence ignored by Muir for a cause-and-effect role for aCL comes from animal models of APS induced by passive and active immunization of rnicef ·10. Animal models have also been used to demonstrate the efficacy of low-dose aspmn in preventing pregnancy loss in experimental APS mice 11.
Even if Muir doubts the cause and effect relationship between aCL and thrombotic vascular disease, he should not dismiss the undisputed association as clinically irrelevant. His negative review fails to stress that as markers of high risk pregnancy, these antibodies are of extreme importance. Collaborative prospective treatment trials ere in progress. Perhaps the more important thing to point out is the conflict that seemed to arise in the minds of many senior medical stalT. They knew that the young man had spent time getting some research under his belt, but noted that he had not been gaining any clinical experience during this time! So the registrar who did not get a Fellowship continued to gain clinical experience and he was the one who got the Senior Registrar job when it came up!
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When I took on MRC Clinical Research
Fellows myself I tried to ensure that these bright young men did continue to gain some clinical experience as well as learning research methods. But now a new problem arose. My consultant colleagues soon found how competent the young men were and tried to take them out of the laboratory at short notice when some crisis arose. I had to 'fight over their bodies'. My colleagues just could not understand that an experiment planned for that afternoon must take precedence over the need for a replacement doctor in the follow-up clinic. õ
